WEBINAR
WEBINAR
Innovative Contracting Mechanisms to Increase the Adoption of Novel Antimicrobials in Latin America
On October 26, 2022, the Americas Health Foundation conducted a virtual webinar on Innovative Contracting Mechanisms to Increase the Adoption of Novel Antimicrobials in Latin America to increase awareness on the topic and inform relevant stakeholders of possible solutions to further access to novel antibiotics.
On October 26th, 2022, the Americas Health Foundation will conduct a virtual webinar on innovative contracting mechanisms for antimicrobial resistance in Latin America to increase awareness on the topic and inform relevant stakeholders on possible solutions to further access to novel antibiotics.
OVERVIEW
OVERVIEW
AMR represents a growing public health threat, responsible for 700,000 annual deaths worldwide, 230,000 of them from multi-drug-resistant tuberculosis. In the Americas, multidrug-resistant microorganisms are the leading cause of health care-associated infections.
There is an urgent need to find access solutions to novel antibiotics in Latin America. Some countries such as the UK, Germany, and France have implemented solutions to reward innovation, including pull mechanisms and innovative payment schemes to increase access to these much-needed medications.
AHF recently carried out a task force about innovative contracting mechanisms to increase access to antimicrobials in Latin America and we would like to continue disseminating knowledge and increasing awareness throughout the region.
AMR represents a growing public health threat, responsible for 700,000 annual deaths worldwide, 230,000 of them from multi-drug-resistant tuberculosis. In the Americas, multidrug-resistant microorganisms are the leading cause of health care-associated infections.
There is an urgent need to find access solutions to novel antibiotics in Latin America. Some countries such as the UK, Germany, and France have implemented solutions to reward innovation, including pull mechanisms and innovative payment schemes to increase access to these much-needed medications.
AHF recently carried out a task force about innovative contracting mechanisms to increase access to antimicrobials in Latin America and we would like to continue disseminating knowledge and increasing awareness throughout the region.
SUMMARY REPORT
OVERVIEW
CLICK HERE to read a final report summarizing all key aspects and conclusions resulting from the event.
AMR represents a growing public health threat, responsible for 700,000 annual deaths worldwide, 230,000 of them from multi-drug-resistant tuberculosis. In the Americas, multidrug-resistant microorganisms are the leading cause of health care-associated infections.
There is an urgent need to find access solutions to novel antibiotics in Latin America. Some countries such as the UK, Germany, and France have implemented solutions to reward innovation, including pull mechanisms and innovative payment schemes to increase access to these much-needed medications.
AHF recently carried out a task force about innovative contracting mechanisms to increase access to antimicrobials in Latin America and we would like to continue disseminating knowledge and increasing awareness throughout the region.
Key Takeaways
OVERVIEW
- Antimicrobial resistance is a serious health threat that has the potential to become an all-out crisis as treatment options dwindle. In Latin America, a quarter of all infections are resistant to antibiotics that are generally used in the first line. This rate could increase to 50% or more in the following decades.
- Timely, safe and stable access to antimicrobials will be essential to mitigate future infectious disease pandemics and antimicrobial resistance.
- In Latin America, there are market failures that limit the development, market sustainability, and access to new antibiotics.
- If introduced, pull incentives may represent a feasible public policy solution to increase access to high-value antimicrobials in the region. Antimicrobials are considered high-value when used to treat infections for which there are few or no other options.
- Pull incentives have been implemented and have proven to be viable in high-income countries and may be viable in Latin America, but dialogue between stakeholders is necessary.
AMR represents a growing public health threat, responsible for 700,000 annual deaths worldwide, 230,000 of them from multi-drug-resistant tuberculosis. In the Americas, multidrug-resistant microorganisms are the leading cause of health care-associated infections.
There is an urgent need to find access solutions to novel antibiotics in Latin America. Some countries such as the UK, Germany, and France have implemented solutions to reward innovation, including pull mechanisms and innovative payment schemes to increase access to these much-needed medications.
AHF recently carried out a task force about innovative contracting mechanisms to increase access to antimicrobials in Latin America and we would like to continue disseminating knowledge and increasing awareness throughout the region.
SPONSORED BY
SPONSORED BY:
SPEAKERS
SPEAKERS
Dr. Waldo Belloso
Director, Innovation Unit - Hospital Italiano de Buenos Aires
Argentina
Dr. Belloso graduated from University of Buenos Aires (UBA), with a specialization in infectious diseases (UBA) and clinical pharmacology (National Ministry of Health). He has a PHD in Statistics for Health Sciences (University of Buenos Aires) and Direction of Incubators, Accelerators and Entrepreneurial Development Sites. He is a professor of Pharmacology at Hospital Italiano de Buenos Aires School of Medicine and Universidad Favaloro and is the head of Externally Sponsored Research at the Research Department. Dr. Belloso is responsible for the Innovation and Technology Transfer Department at Hospital Italiano de Buenos Aires. He is the former Head of Clinical Pharmacology Section at Hospital Italiano de Buenos Aires and former Deputy Administrator at National Administration of Drugs, Food and Medical Technology (ANMAT). Dr. Belloso has over 85 peer-reviewed publications. Research areas: pharmacology of antiviral drugs, metabolic complications of HIV disease, pharmacogenomics, and appropriate use of antimicrobials.
Dr. Belloso graduated from University of Buenos Aires (UBA), with a specialization in infectious diseases (UBA) and clinical pharmacology (National Ministry of Health). He has a PHD in Statistics for Health Sciences (University of Buenos Aires) and Direction of Incubators, Accelerators and Entrepreneurial Development Sites. He is a professor of Pharmacology at Hospital Italiano de Buenos Aires School of Medicine and Universidad Favaloro and is the head of Externally Sponsored Research at the Research Department. Dr. Belloso is responsible for the Innovation and Technology Transfer Department at Hospital Italiano de Buenos Aires. He is the former Head of Clinical Pharmacology Section at Hospital Italiano de Buenos Aires and former Deputy Administrator at National Administration of Drugs, Food and Medical Technology (ANMAT). Dr. Belloso has over 85 peer-reviewed publications. Research areas: pharmacology of antiviral drugs, metabolic complications of HIV disease, pharmacogenomics, and appropriate use of antimicrobials.
Dr. Maria Luisa Avila
Chief of Infectiology at Hospital Nacional
San Jose, Costa Rica
Dr. Maria Luisa Avilia-Aguero is pediatric infectiologist and Head of the Infectiology Department at Hospital Nacional de Niños Dr. Carlos Sáenz Herrera, Costa Rica. She is Associate Professor of the Pediatric at the University of Costa Rica. She is also director of Post-Graduate Studies in Pediatric Infectious Diseases at the University of Costa Rica. Dr. Avila is the former Minister of Health for Costa Rica (2006–2011) and former Director of the Committee of Nosocomial Infections (1999–2005). She has won several awards, including the 50 most influential women in Central America by Forbes, among several others. She is a member of the Council of International Society for Infectious Diseases and is a researcher affiliated with the Center for Modeling and Analysis of Infectious Diseases, Yale University (2018–present).
Dr. Maria Luisa Avilia-Aguero is pediatric infectiologist and Head of the Infectiology Department at Hospital Nacional de Niños Dr. Carlos Sáenz Herrera, Costa Rica. She is Associate Professor of the Pediatric at the University of Costa Rica. She is also director of Post-Graduate Studies in Pediatric Infectious Diseases at the University of Costa Rica. Dr. Avila is the former Minister of Health for Costa Rica (2006–2011) and former Director of the Committee of Nosocomial Infections (1999–2005). She has won several awards, including the 50 most influential women in Central America by Forbes, among several others. She is a member of the Council of International Society for Infectious Diseases and is a researcher affiliated with the Center for Modeling and Analysis of Infectious Diseases, Yale University (2018–present).
Dr. Javier Guzman
Director of Health Policy at Center for Global Development
Washington D.C
Dr. Javier Guzman is the director of Global Health Policy and a Senior Policy Fellow at the Center for Global Development. He is the former Technical Director of the USAID-funded Medicines, Technologies, and Pharmaceutical Services (MTaPS) Program at Management Sciences for Health (MSH) and has played different roles within the Colombian government between 2013 and 2018: Deputy Director of the health technology assessment agency; Director of Medicines and Health Technologies at the Ministry of Health; and Director General of the Colombian Food and Drug Surveillance Institute, one of the eight National Regulatory Authorities of regional reference in the Americas. Prior work history includes the following positions: physician, researcher, analyst and policy maker in the United States, the United Kingdom, Australia, and his native Colombia. Dr. Guzman’s interests include, how global health challenges such as Covid and antimicrobial resistance, can offer a window of opportunity to improve the efficiency and effectiveness of global institutions and build more sustainable and equitable health systems.
Dr. Javier Guzman is the director of Global Health Policy and a Senior Policy Fellow at the Center for Global Development. He is the former Technical Director of the USAID-funded Medicines, Technologies, and Pharmaceutical Services (MTaPS) Program at Management Sciences for Health (MSH) and has played different roles within the Colombian government between 2013 and 2018: Deputy Director of the health technology assessment agency; Director of Medicines and Health Technologies at the Ministry of Health; and Director General of the Colombian Food and Drug Surveillance Institute, one of the eight National Regulatory Authorities of regional reference in the Americas. Prior work history includes the following positions: physician, researcher, analyst and policy maker in the United States, the United Kingdom, Australia, and his native Colombia. Dr. Guzman’s interests include, how global health challenges such as Covid and antimicrobial resistance, can offer a window of opportunity to improve the efficiency and effectiveness of global institutions and build more sustainable and equitable health systems.
Dr. Diego Guarin
Regional Market Access Lead for Latin America, MSD
Dr. Diego Guarin is the Regional Market Access Lead for Latin America at Merck (known as MSD outside USA and Canada), focusing on improving patient access to health innovations. He has been head of Regional Market Access and Evidence and Value Development (HEOR) teams at top global biopharmaceutical companies since 2018. Dr. Guarin has been a key contributor to the development of Pharmacoeconomics and Outcomes Research in Latin America since 2007. He has been a Company representative at FIFARMA since 2013 and Co-chair of two working groups at the Latin American Federation of the Pharmaceutical Industry (Value and Access to Innovation: 2017-20/2021-22 and Health Policies: 2022-to date). Dr. Guarin graduated as a Medical Doctor from Universidad del Rosario-1653 (Colombia) and has a Master’s in Public Health in Developing Countries from the London School of Hygiene and Tropical Medicine (UK); Health Economics and Pharmacoeconomics from Universitat Pompeu Fabra (Spain); and in Health Economics Policy and Management from the London School of Economics and Political Science (UK).
Dr. Diego Guarin is the Regional Market Access Lead for Latin America at Merck (known as MSD outside USA and Canada), focusing on improving patient access to health innovations. He has been head of Regional Market Access and Evidence and Value Development (HEOR) teams at top global biopharmaceutical companies since 2018. Dr. Guarin has been a key contributor to the development of Pharmacoeconomics and Outcomes Research in Latin America since 2007. He has been a Company representative at FIFARMA since 2013 and Co-chair of two working groups at the Latin American Federation of the Pharmaceutical Industry (Value and Access to Innovation: 2017-20/2021-22 and Health Policies: 2022-to date). Dr. Guarin graduated as a Medical Doctor from Universidad del Rosario-1653 (Colombia) and has a Master’s in Public Health in Developing Countries from the London School of Hygiene and Tropical Medicine (UK); Health Economics and Pharmacoeconomics from Universitat Pompeu Fabra (Spain); and in Health Economics Policy and Management from the London School of Economics and Political Science (UK).
MODERATOR
MODERATOR
Dr. Mariana Rico
Medical Director for AHF
Colombia
Dr. Mariana Rico is the Medical Director for the Americas Health Foundation. She is a physician based in Bogotá, Colombia dedicated to promoting equitable access to healthcare in Latin America. She has broad experience in public health policy, focusing on healthcare access barriers and inequities, and advocacy solutions in many different fields including rare diseases, oncology, autoimmune and infectious diseases, and women's health. She has been a key contributor to public health and equal access issues in Colombia, having worked with multiple underserved rural communities across the country, developing and implementing strategic integrated healthcare strategies based on population health diagnostics to optimize healthcare potential in vulnerable populations. She has led over 20 consensus conferences, task forces, and reports on these topics during her time at AHF.
Dr. Mariana Rico is the Medical Director for the Americas Health Foundation. She is a physician based in Bogotá, Colombia dedicated to promoting equitable access to healthcare in Latin America. She has broad experience in public health policy, focusing on healthcare access barriers and inequities, and advocacy solutions in many different fields including rare diseases, oncology, autoimmune and infectious diseases, and women's health. She has been a key contributor to public health and equal access issues in Colombia, having worked with multiple underserved rural communities across the country, developing and implementing strategic integrated healthcare strategies based on population health diagnostics to optimize healthcare potential in vulnerable populations. She has led over 20 consensus conferences, task forces, and reports on these topics during her time at AHF.
HOSTED BY
HOSTED BY
JOIN OUR NEWSLETTER
JOIN OUR NEWSLETTER
Suscribe our newsletter to receive the latest news.
Suscribe our newsletter to receive the latest news.
CONTACT US
Phone: 1+(202) 650-7080
Email: tvidal@the-ahf.org
909 New Jersey Avenue SE
Suite 1101
Washington, DC 20003
Americas Health Foundation is a 501 (c)(3), non-profit foundation.